Meeting News

Posted: February 2018 During the past few years, improvements in the knowledge of immune system biology have dramatically changed the therapeutic paradigm for NSCLC. Pembrolizumab has been recently approved by regulatory agencies as an upfront agent for patients with advanced NSCLC with 50% or greater programmed cell death ligand 1 (PD-L1) expression, and recent data…

New collaborative meeting to provide educational, scientific updates to diverse audience from Africa and the Middle East. By Joy Curzio, ILCN Managing Editor Posted: February 2018 As a global association, the IASLC understands the numerous variables, experiences, and perspectives that dictate a country’s or region’s ability to be a principal actor in scientific events. For…

By Monte M. Winslow, PhD Posted: February 2018 Over 4 rainy days in San Diego, California, more than 220 participants from 15 different countries heard presentations that spanned a very wide range of basic, translational, and clinical lung cancer research. This joint conference between the IASLC and the American Association for Cancer Research (AACR) was…

By Cynthia L. Kryder, MS and Lori L. Alexander, MTPW, ELS, MWC Posted: December 2017 An oral abstract session at the IASLC World Conference on Lung Cancer (WCLC) 2017 drew a standing-roomonly crowd to hear updates on studies of 3 immunotherapy drugs: pembrolizumab, nivolumab, and atezolizumab, and their role in advanced non-small cell lung cancer…

By Luis E. Raez, MD Posted: December 2017 Under the sponsorship of the IASLC, the Peruvian Association for Bronchology and Interventional Pulmonology (APBNI) organized a seminar on bronchoscopy ultrasound (EBUS) and navigational bronchoscopy in Lima, Peru, on July 21, 2017. IASLC members Dr. Pedro Garcia-Mantilla, a pulmonologist at the Guillermo Almenara Hospital in Lima, and…

By Jyoti Patel, MD, and Heather A. Wakelee, MD Posted: December 2017 The IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology was held September 14-16, 2017 and brought together nearly 400 participants to discuss important topics in lung cancer prevention, detection, and care. The multidisciplinary nature of the meeting was most apparent in the initial…

By Cynthia L. Kryder, MS Posted: December 2017 The IASLC WCLC 2017 Presidential Symposium in Yokohama, Japan, recognized the authors of 3 exceptional lung cancer research abstracts. Patient-reported Outcomes from the PACIFIC Trial According to previously reported efficacy and safety results of the PACIFIC trial, patients with locally advanced stage III NSCLC receiving durvalumab post…

Posted: October 2017 At the upcoming IASLC WCLC 2017 Conference, Co-Presidents Hisao Asamura, MD, and Keunchil Park, MD, PhD, will welcome delegates from more than 100 countries who will gather to witness and discuss the latest developments in thoracic malignancy research. The WCLC 2017 motto “Synergy to Conquer Lung Cancer” captures the collaborative spirit of…

By Luis E. Raez, MD The IASLC-Latin American Group (LATAM) successfully organized another “Workshop in Lung Cancer Clinical Research,” as it has done before in other countries like Chile and Peru. Dr. Christian Rolfo and Dr. Luis Corrales chaired the workshop. They were joined by another 10 IASLC faculty from LATAM, including Drs. Luis E.…

Posted: June 2017 By Keightley Amen, BA, ELS In early May, at the seventh annual European Lung Cancer Conference (ELCC) in Geneva, Switzerland, multidisciplinary lung cancer professionals gathered to learn about the latest research advances in the field. Men Require More Frequent Screening for Lung Cancer A study presented at ELCC retrospectively reviewed patients who…